Bb Biotech News Today

[applause] thank you are coming. Its my pleasure to introduce to you, commissioner michael bueller. He was appointed to the Security Commission by president obama and is sworn in an august 2013. He was delegated by President Trump to be in german in that capacity from january 23rd of this year to may 4th. His term expires in june 2018. Previously, dr. Pirowar worked at the sec in the office of Economic Analysis with the division of economic and risk analysis as an academic scholar from iowa stat...

While 30-years ago biotechnology was a very young industry there is now a broad mix of large companies and smaller providers with candidates.

By Andrea Figueras BB Biotech on Friday reported a narrowed after-tax loss for the second quarter as it booked sharply reduced losses from investments, and...

17.02.2023 - EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Annual Report BB Biotech AG publishes its 2022 annual report 17-Feb-2023 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS ... Seite 1

21.10.2022 - EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report BB Biotech AG publishes its interim report 21-Oct-2022 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - ...

The steadily growing importance of small and mid-cap biotech companies has not yet been fully acknowledged by financial markets.

Biotech companies that became popular with investors during the pandemic are now falling out of favour.

Investment Week’s Alex Rolandi asks Dallas Webb, portfolio manager at BB Biotech, what the future holds for biotechnology.

Biotech investors and analysts are looking to the new year with optimism following poor performance in 2021.

The pandemic has acted as a catalyst for the biotechnology and health industries, accelerating the pace at which new technologies are being adopted.